Gene Therapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenocarcinoma
Studies from University of Halle-Wittenberg yield new data on adenocarcinoma
November 12th, 2009
"Transforming growth factor-beta 1 (TGF-beta 1) is over-expressed in a variety of malignant epithelial tumors and was suggested to be a marker of colorectal cancer. Moreover, there is growing evidence that TGF-beta 1 contributes to tumor progression by regulating tumor cell proliferation and differentiation, inducing a favorable tumor microenvironment, promoting migration and invasion, and suppressing macrophage cytotoxicity," scientists in Halle, Germany report. "Therefore, we stably transfected an anti-TGF-beta 1 hammerhead ribozyme into the human colorectal adenocarcinoma cell line HRT-18. Expression of this ribozyme resulted in significant inhibition of TGF-beta 1...
Source: Gene Therapy Weekly (2009-11-12)
|
